NCT01752322已完成3 期
Efficacy and Safety of Lidocaine 5% Medicated Plaster in Localized Chronic Post-operative Neuropathic Pain
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 444
- 试验地点
- 42
- 主要终点
- Change from baseline of recorded average pain intensity values during the last 24 hours, averaged over the 7 days of Week 12 of the Double-blind Treatment Period.
研究概览
简要总结
The purpose of this trial is to investigate the efficacy and safety of lidocaine 5% medicated plaster in localized chronic post-operative neuropathic pain in comparison to placebo plaster.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects aged 18 years or older.
- •Subjects suffering from moderate to severe localized chronic PoNP (post operative neuropathic pain) pain following surgery (e.g., thoracotomy, total/partial knee replacement, cholecystectomy, mastectomy, inguinal hernia repair, varicose vein stripping).
- •Localized PoNP present for at least 3 months.
- •Size of the affected painful skin area is not larger than the size of 3 plasters.
- •Intact skin besides the scar of surgery in the area of plasters application
- •Baseline average pain intensity of 4 or greater on the 11 point pain intensity Numeric Rating Scale.
排除标准
- •Participation in another trial (with medicine or a device under investigation) in parallel or less than 30 days prior to enrollment in this trial.
- •Previous enrollment in this trial.
- •History of dependency or active drug abuse (alcohol, medication) during the 1 year prior to enrollment.
- •Evidence or history (during the 3 years prior to enrollment) of neurotic personality or psychiatric illness that in the investigator's opinion may affect efficacy or safety assessments or may compromise the subjects safety during trial participation.
- •Pregnant or breastfeeding women or women of childbearing potential who are sexually active without satisfactory contraception.
- •Any surgery performed in the 3 months prior to enrollment, which may affect efficacy or safety assessment.
- •Any surgery scheduled or expected during the trial.
- •Clinically significant disease (e.g., acquired immunodeficiency syndrome) or condition that may affect efficacy or safety assessments, or any other reason which, in investigator's opinion, may preclude the subject's participation in the trial.
- •History of malignancy (with the exception of neoplasia related to the trial indication) within 2 years prior to enrollment.
- •Subject with PoNP related to a surgery due to neoplasia: suspected residual neoplasia or metastases.
- •Pending litigation due to chronic pain or disability.
- •Total anesthesia in the cutaneous area neurologically related to the location of the surgical intervention.
- •Hypersensitivity to the lidocaine 5% medicated plaster, its excipients, or anesthetics of the amide type.
- •Any former use of topical lidocaine in the area of localized chronic PoNP.
- •Severe renal, hepatic or heart disorder.
研究组 & 干预措施
Lidocaine plaster
Experimental
Topical hydrogel plaster
干预措施: Lidocaine 5% medicated plaster (Drug)
Placebo plaster
Placebo Comparator
Topical hydrogel plaster
干预措施: Placebo plaster (Drug)
结局指标
主要结局
Change from baseline of recorded average pain intensity values during the last 24 hours, averaged over the 7 days of Week 12 of the Double-blind Treatment Period.
时间窗: Days 78-85
次要结局
- Mean pain intensity based on the current pain intensity before plaster removal, calculated over the last 7 days, 4 weeks, and 12 weeks of the Double blind Treatment Period.(up to 12 weeks)
- Mean pain intensity based on the average pain intensity during the last 24 hours, calculated over the last 4 weeks and 12 weeks of the Double blind Treatment Period.(up to 12 weeks)
- Weekly mean pain intensity before plaster removal based on the average pain intensity during the last 24 hours.(up to 12 weeks)
- Weekly mean pain intensity before plaster removal based on current pain intensity before plaster removal.(up to 12 weeks)
- Final score of the painDETECT Pain Questionnaire during the Double blind Treatment Period.(Day 85)
- Pain intensity from mechanical dynamic allodynia (brush) testing.(Day 85)
- Anxiety and depression scores of HADS.(Day 85)
- The weighted Health Status Index of quality of life by means of EQ 5D.(Day 85)
- Total score in quality of sleep using CPSI.(Day 85)
- Mean pain intensity change from baseline based on the average pain intensity during the last 24 hours, calculated over the last 4 weeks and 12 weeks of the Double blind Treatment Period.(up to 12 weeks)
- Mean pain intensity change from baseline based on the current pain intensity before plaster removal, calculated over the last 7 days, 4 weeks, and 12 weeks of the Double blind Treatment Period.(up to 12 weeks)
- Weekly mean pain intensity change from baseline before plaster removal based on the average pain intensity during the last 24 hours.(up to 12 weeks)
- Weekly mean pain intensity change from baseline before plaster removal based on current pain intensity before plaster removal.(up to 12 weeks)
- Change from baseline in the total score of the painDETECT Pain Questionnaire during the Double blind Treatment Period.(Day 85)
- Change from baseline in pain intensity from mechanical dynamic allodynia (brush) testing.(Day 85)
- Change from baseline in anxiety and depression scores of HADS.(Day 85)
- Change from baseline in total score of quality of life by means of EQ 5D.(Day 85)
- Change from baseline in total score in quality of sleep using CPSI.(Day 85)
研究者
研究点 (42)
Loading locations...
相似试验
终止
2 期
Lidocaine 5% Medicated Plaster in Chronic Neuropathic Postoperative PainPainChronic PainNeuropathic PainPostoperative PainNCT01155986Grünenthal GmbH74
进行中（未招募）
1 期
Efficacy and tolerability of lidocaine for long-term local nerve paiEUCTR2012-000347-28-ESGrünenthal GmbH360
进行中（未招募）
1 期
Efficacy and tolerability of lidocaine for long-term local nerve paimoderate to severe localized chronic post-operative neuropathic painMedDRA version: 14.1Level: LLTClassification code 10054095Term: Neuropathic painSystem Organ Class: 10029205 - Nervous system disordersEUCTR2012-000347-28-ATGrünenthal GmbH360
进行中（未招募）
1 期
Efficacy and tolerability of lidocaine for long-term local nerve paimoderate to severe localized chronic post-operative neuropathic painMedDRA version: 14.1Level: LLTClassification code 10054095Term: Neuropathic painSystem Organ Class: 100000004852EUCTR2012-000347-28-GBGrünenthal GmbH360
进行中（未招募）
1 期
Efficacy and tolerability of lidocaine for long-term local nerve paimoderate to severe localized chronic post-operative neuropathic painMedDRA version: 17.1Level: LLTClassification code 10054095Term: Neuropathic painSystem Organ Class: 100000004852EUCTR2012-000347-28-DKGrünenthal GmbH360